Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Cantor Fitzgerald
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $150.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential downside of 39.42% from the stock’s current price. A number […]
More Stories
One Hundred Years of Solitude Season 2: Release Date, Cast Members, Trailer, and More
The best-selling novel One Hundred Years of Solitude by Nobel Prize-winning Colombian author García Márquez is coming back as a...
When Your Payment Provider Can No Longer Keep Up
A payment account can work perfectly well until the business starts growing. Sales rise and customers arrive from new countries,...
The Hawk Season 2 Updates: Where Did Season 1 End
Netflix’s 2026 series, The Hawk, has been released. It has received a mixed response from the audience in different parts...
Netflix’s Upcoming Sports Documentary: Mourinho Is Releasing Soon
Football fans, be ready! Netflix is about to drop one of its most-awaited sports documentaries of 2026. Mourinho is a...
Order of the Sinking Star is Ready to Launch on PlayStation 5 and TV
The creator of Braid and The Witness, Jonathan Blow, is returning with an all-new puzzle video game, Order of the...
Netflix’s Upcoming Drama, All the Truth in My Lies: Release Date, Cast, and More
Excited to know about the upcoming Spanish drama on Netflix, All the Truth in My Lies. If you love watching...